Abstract:Toll-like receptor 4 (TLR4) is a toll-like receptor (TLR) family protein that organizes an innate immune response that distinguishes nonself and endogenous danger signals. Specifically, TLR4 recognizes lipopolysaccharide (LPS) from the cell wall of Gram-negative bacteria, as well as endogenous signals such as HSP60, HSP70, and fibrinogen. Agonism of the receptor is dependent upon a homodimeric TLR4 signaling complex that ACHTUNGTRENNUNGincludes myeloid differentiation factor 2 (MD2). The assembly of the TLR4–MD2 complex initiates a MyD88-dependent signaling cascade, which relocates nuclear factor-kB (NF-kB) from the cytoplasm to the nucleus. Transcription by the NF-kB promoter directs the production of a number of proinflammatory cytokines including TNFa, IL-1b, IL-6, and IFN-g. Recent evidence suggests that TLR4-mediated elevations in the expression of these cytokines in glia cells and astrocytes in the central nervous system (CNS) initiate and propagate several debilitating disease states such as chronic pain and sepsis. The lack of good clinical treatments for chronic pain has made its effectors, including TLR4, popular targets for new therapeutics. Chronic pain occurs in epidemic proportions worldwide. The disease typically arises from two types of injuries : 1) tissue injuries that lead to inflammatory pain, and 2) nerve injuries that lead to neuropathic pain. Microglia in the CNS recognize a variety of signals associated with inflammatory or nerve injury and subsequently release a variety of inflammatory mediators in response, including TNFa, IL-1b, IL-6, PGE-2, COX-2, and ATP. The release of these molecules stimulates other glia to respond in a proinflammatory manner, and also results in neuronal actions. Stimulation of nociceptive pain neurons by glial inflammatory mediators leads to hypersensitivity and enhanced pain states. This centrally mediated pathological pain causes exaggerated pain sensitivity in healthy and undamaged tissues. The hypersensitive state leads to intense and exaggerated pain being sensed from both painful (hyperalgesia) and/or nonpainful stimuli (allodynia). 8] Previous research has indicated that TLR4 plays a major role in the development of chronic pain. TLR4 is now well documented to become activated by so-called “endogenous danger signals”. These are substances released by stressed or damaged cells (such as the HMGB-1, and HSP proteins, etc.) that signal distress of host cells through TLR4 signaling, which leads to glial release of proinflammatory mediators. In fact, TLR4-knockout mice that have undergone nerve injury do not develop allodynia and show reduced glial activation with lower levels of pain-related mediators. Moreover, hypersensitivity can be attenuated in chronic pain rats by using a TLR4 antisense oligonucleotide. TLR4 signaling is dependent upon the formation of a homodimer, which is mediated by the accessory protein MD2. 14] Specific point mutations to MD2 (for example, Cys95Tyr), which prevent its association with TLR4, significantly diminishes TLR4 signaling. TLR4-based peptides or TLR4-MD2 fusion proteins can also attenuate signaling by competing for MD2 or LPS respectively . 17] Given the wide array of agonists that TLR4 recognizes, it is not clear whether a peptide that targets TLR4 directly would agonize or antagonize the receptor. The recently reported high-resolution X-ray crystal structure of the murine TLR4–MD2 complex revealed several molecular recognition sites on the TLR4–MD2 interface that could serve as potential targets for a peptide. A charged patch spanning from Asp99 to Glu111 (critical charged residues are underlined in Table 1) of MD2 was projected to be critical to the nanomolar binding affinity of MD2 and TLR4. These charged residues are projected by a short a helix (Ser103–Lys109) and a random-coil protruding loop (Cys95–Tyr102) that is constrained by a disulfide bridge between Cys95 and Cys105. Herein, we employed a chemical biology approach by utilizing the minimal TLR4binding region of MD2 to block the TLR4–MD2 association. The in silico, in vitro, and whole-cell data demonstrated for the

A Peptide That Antagonizes TCR-Mediated Reactions with Both Syngeneic and Allogeneic Agonists: Functional and Structural Aspects

Synthesis and Biological Activities of Amino Acids Functionalized Α-Galcer Analogues.

Modification of peptide interaction with MHC creates TCR partial agonists

Novel Cocrystal Structures of Peptide Antagonists Bound to the Human Melanocortin Receptor 4 Unveil Unexplored Grounds for Structure-Based Drug Design

Synthetic Peptides with Inadvertent Chemical Modifications Can Activate Potentially Autoreactive T Cells

Conformation of neuropeptide Y receptor antagonists: structural implications in receptor selectivity

Deciphering specificity and cross-reactivity in tachykinin NK1 and NK2 receptors

Structural Requirements for Tyr in the Consensus Sequence Y-E-N of a Novel Nonphosphorylated Inhibitor to the Grb2-SH2 Domain.

A Novel TNFα Antagonizing Peptide-Fc Fusion Protein Designed Based on CDRs of TNFα Neutralizing Monoclonal Antibody

Characterization of Amino Acid Residues of T-cell Receptors Interacting with HLA-A*02-restricted Antigen Peptides

De Novo Design TNF-α Antagonistic Peptide Based on the Complex Structure of TNF-α with Its Neutralizing Monoclonal Antibody Z12

Development of chimeric and bifunctional antagonists for CLR/RAMP receptors

Abstract LB442: Novel antibodies against a KK-LC-1-derived peptide presented on HLA-A*01 on tumor cells

Peptide-dependent inhibition of alloreactive T-cell response by soluble divalent HLA-A2/IgG molecule in vitro.

Use of phosphotyrosine-containing peptides to target SH2 domains: Antagonist peptides of the Crk/CrkL-p130Cas axis

Specificity and binding properties of a single-chain T cell receptor

A Peptide Antagonist of the TLR 4 – MD 2 Interaction

Structural basis for self-discrimination by neoantigen-specific TCRs

A Synthetic Bivalent Peptide Ligand of EphB4 with Potent Agonistic Activity

Computational Modeling and Characterization of Peptides Derived from Nanobody Complementary-Determining Region 2 (CDR2) Targeting Active-State Conformation of the β2-Adrenergic Receptor (β2AR)

Molecular basis for allosteric agonism and G protein subtype selectivity of galanin receptors